|
| 37442024 | Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? | Gynecol Oncol | 2023 |
| 37287928 | Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile. | Front Oncol | 2023 |
| 37253112 | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. | Cancer Res | 2023 |
| 37212177 | Epigenomics may begin to explain <i>in vitro</i> differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer. | Epigenomics | 2023 |
| 34654724 | Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. | Cancer Res | 2022 |
| 35472731 | Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. | Transl Oncol | 2022 |
| 35519002 | High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. | Gynecol Oncol Rep | 2022 |
| 36454788 | ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer. | PLoS One | 2022 |
| 35875052 | DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model. | NAR Cancer | 2022 |
| 36274096 | Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. | Nat Commun | 2022 |
| 36244826 | Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer. | Gynecol Oncol | 2022 |
| 36082022 | GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. | Cancer Res Commun | 2022 |
| 34810199 | Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. | Cancer Res | 2022 |
| 33407429 | Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness. | BMC Med Inform Decis Mak | 2021 |
| 33602789 | GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. | Cancer Res | 2021 |
| 33850213 | Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. | Sci Rep | 2021 |
| 33507295 | Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. | Blood | 2021 |
| 33503056 | Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. | PLoS One | 2021 |
| 33771896 | Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. | Cancer Res | 2021 |
| 34885153 | CHFR and Paclitaxel Sensitivity of Ovarian Cancer. | Cancers (Basel) | 2021 |
| 35028612 | Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. | Cell Rep Med | 2021 |
| 34588438 | SPOP mutation induces DNA methylation via stabilizing GLP/G9a. | Nat Commun | 2021 |
| 34702806 | Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. | Cell Death Dis | 2021 |
| 34385422 | Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. | Cell Death Dis | 2021 |
| 34101624 | FOXA1 overexpression suppresses interferon signaling and immune response in cancer. | J Clin Invest | 2021 |
| 34321239 | Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. | Cancer Res | 2021 |
| 34316715 | Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. | NAR Cancer | 2021 |
| 32260077 | Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. | Cancers (Basel) | 2020 |
| 34567703 | A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. | Microsyst Nanoeng | 2020 |
| 32060098 | The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. | Clin Cancer Res | 2020 |
| 31714594 | Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. | Cancer | 2020 |
| 32104500 | Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. | Theranostics | 2020 |
| 33109627 | Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. | ESMO Open | 2020 |
| 33057068 | Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. | Nat Commun | 2020 |
| 32929152 | Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. | Oncogene | 2020 |
| 30499260 | Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. | Mol Oncol | 2019 |
| 31751381 | Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. | PLoS One | 2019 |
| 31204077 | Genes associated with bowel metastases in ovarian cancer. | Gynecol Oncol | 2019 |
| 31371750 | Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. | Sci Rep | 2019 |
| 31619387 | BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. | Cancer Res | 2019 |
| 31004097 | Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. | Sci Rep | 2019 |
| 30723117 | EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. | EMBO J | 2019 |
| 29788332 | Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. | J Natl Cancer Inst | 2018 |
| 29967001 | Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. | Cancer Epidemiol Biomarkers Prev | 2018 |
| 29988130 | Senolytics improve physical function and increase lifespan in old age. | Nat Med | 2018 |
| 30087253 | LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer. | Cancers (Basel) | 2018 |
| 29550183 | Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. | Gynecol Oncol | 2018 |
| 29523594 | Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in <i>PTEN</i>- or <i>SPOP</i>-mutated prostate cancer. | EMBO Mol Med | 2018 |
| 29724109 | Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. | Am J Hosp Palliat Care | 2018 |
| 28658648 | Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. | Neoplasia | 2017 |